Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c

Reports Q3 revenue $316.18M, consensus $317.33M. “Despite a dynamic macroenvironment, the Bio-Techne (TECH) team once again executed at a high level and delivered strong third quarter results,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Our pharma end market continued to improve, especially from our large pharma partners, which led to a solid performance in our cell therapy and protein analysis instrumentation businesses. Our continued focus on profitability resulted in a 34.9% adjusted operating margin, an increase of 190 basis points compared to the prior year period.”